Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials.
Li WangYibo FeiHan QuHaiyang ZhangYuanyuan WangZhenghua WuGuorong FanPublished in: Journal of pharmaceutical health care and sciences (2024)
The frequent adverse reactions of bevacizumab occurring in the real world are consistent with the data provided in RCTs and drug specifications. However, adverse reactions such as nasal septum perforation, necrotizing fasciitis, hypertensive encephalopathy and so on, listed as rare in drug specifications, may have a high signal of correlation in the real world, which all requires active monitoring and timely adjustment of bevacizumab posology during its clinical use.